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Highlights 
 Ca2+ overload is responsible for initiation of pancreatic pathology in AP  Mechanism of Asparaginase-induced AP is similar to alcohol- and bile- induced AP  Pharmacological interventions in pancreatic stellate cells provide additional opportunities 
for developing of AP treatments 
 
 
Abstract 
In spite of significant scientific progress in recent years, acute pancreatitis (AP) is still a 
dangerous and in up to 5% of cases deadly disease with no specific cure. It is self-resolved in the 
majority of cases, but could result in chronic pancreatitis (CP) and increased risk of pancreatic 
cancer (PC). One of the early events in AP is premature activation of digestive pro-enzymes, 
including trypsinogen, inside pancreatic acinar cells (PACs) due to an excessive rise in the 
cytosolic Ca2+ concentration, which is the result of Ca2+ release from internal stores followed by 
Ca2+ entry through the store operated Ca2+ channels in the plasma membrane. The leading 
causes of AP are high alcohol intake and biliary disease with gallstones obstruction leading to 
bile reflux into the pancreatic duct. Recently attention in this area of research turned to another 
cause of AP - Asparaginase based drugs – which have been used quite successfully in treatments 
of childhood acute lymphoblastic leukaemia (ALL). Unfortunately, Asparaginase is implicated 
in triggering AP in 5-10% of cases as a side effect of the anti-cancer therapy.  The main features 
of Asparaginase-elicited AP (AAP) were found to be remarkably similar to AP induced by 
alcohol metabolites and bile acids. Several potential therapeutic avenues in counteracting AAP 
have been suggested and could also be useful for dealing with AP induced by other causes. 
Another interesting development in this field includes recent research related to pancreatic 
stellate cells (PSCs) that are much less studied in their natural environment but nevertheless 
critically involved in AP, CP and PC. This review will attempt to evaluate developments, 
approaches and potential therapies for AP and discuss links to other relevant diseases. 
 
 
Introduction 
Acute pancreatitis (AP) is a disease usually caused by alcohol abuse or bile reflux due to gallstones. 
Other causes include some type of antibiotics, chemotherapy, infections, certain rare conditions and 
others [1]. One of the complications that can result from AP is chronic pancreatitis (CP) that 
significantly increases risk of pancreatic cancer [2-5]. AP is a severe disease and has a significant 
mortality of about 5% [1, 3]. However, in severe cases, the mortality rate can rise to 30% [6], with 
significant pancreatic acinar cell (PAC) necrosis followed by a damaging inflammatory response. The 
leading causes of AP have been identified as gallstone biliary disease and high alcohol intake, while 
abnormality in calcium signalling in PACs was found to be one of the first events in the initiation of 
AP [3].  
 
Physiological calcium signalling in PACs 
Calcium signalling plays a fundamental role in regulation of digestive enzymes and fluids secretion 
by the exocrine pancreas [7]. A range of endogenous stimuli such as the neurotransmitter 
acetylcholine (ACh) [8] produced by the vagal nerve endings and the hormone cholecystokinin (CCK) 
secreted by enteroendocrine I cells of the small intestine [9,10] serve as triggers in the activation of 
the calcium signalling machinery. Binding of ACh to the muscarinic receptor type 3, which is a G-
protein-coupled receptor, results in activation of phospholipase C and production of the second 
messenger inositol trisphosphate (IP3) that induces Ca2+ release from the internal stores through IP3 
receptors [11]. In fact, in the absence of IP3 receptors or type 2 and 3 (double-knockout), carbachol -
induced secretion is completely abolished in PACs [12]. Similarly, Ca2+ release in PACs elicited by 
physiological doses of CCK, also in the human pancreas [13,14], is primarily mediated by nicotinic 
acid adenine dinucleotide phosphate (NAADP). In this case the action depends on functional 
ryanodine receptors (RyRs) and two-pore channels (TPCs) and also involves acid Ca2+ stores 
[15,16,17,18]. Calcium response then further amplified by calcium induced calcium release (CICR) 
from the acid stores and the ER [17,18]. While the exact mechanism of the NAADP production and 
action remains elusive, in PACs NAADP-induced calcium responses are linked to both ER and acidic 
stores, and is highly depend on RyR type 1 and TPC type 2 [18]. A hypothesis that takes into account 
practically all published data suggests a mechanism involving 3 stores: an initial, virtually 
undetectable, NAADP-elicited Ca2+release via TPCs from endosomes/lysosomes triggers the 
detectable Ca2+-induced Ca2+ release via RyR1 and RyR3 occurring from the granules and the ER. 
Both pathways result in feeding of Ca2+ to the cytosol and subsequent exocytosis of zymogen granule 
content into the acinar lumen that, together with fluid supplemented with bicarbonate, is transported 
via the pancreatic duct system to the duodenum under physiological conditions [17,18]. 
Pathological calcium signalling in PACs 
In AP, the pancreatic proenzymes such as trypsinogen become prematurely activated intracellularly, 
resulting in the molecular cannibalism that digests pancreas and its surroundings [3,6]. There is 
overwhelming evidence, collected during last two decades, implicating abnormal cytosolic Ca2+ 
overload in the initiation and development of AP [3,19-23]. The most damaging are the sustained 
elevations in [Ca2+], from high concentrations of some secretagogues, as well as from ductal 
hypertension, alcohol, hypoxia, hypercalcaemia, hyperlipidaemia, viral infection, and various drugs—
all factors known to precipitate acute pancreatitis [19, 24]. These factors cause either excessive 
release of acinar [Ca2+]i, or damage to the integrity of mechanisms that restore low resting levels of 
[Ca2+]i, and the consequent calcium toxicity become the key trigger of acute pancreatitis [19,20]. 
Aberrant calcium signalling, as the main initiation event in AP, has been proposed more than two 
decades ago and became the widely accepted mechanistic explanation [19,20,25]. Pathological 
stimuli, such as bile and alcohol, are capable of triggering massive Ca2+ release from intracellular 
stores through IP3Rs and RyRs followed by excessive Ca2+ entry through Ca2+ release activated Ca2+ 
(CRAC) channels that are the most important mechanisms of Ca2+ overload in pancreatic acinar cells 
[3,26].  
It has been shown that long lasting Ca2+ responses with a development of a sustained elevated 
cytosolic Ca2+ plateau component result in destabilisation of the secretory zymogen granules and 
conversion of them into empty looking vacuoles [27].  Intracellular vacuolisation [4], causes another 
calcium-dependent process, intracellular protease (trypsin) activation [5]. As a result, the inactive 
pancreatic pro-enzymes stored in zymogen granules (ZG) become active enzymes inside the PACs 
[21,27], inducing mitochondrial malfunction [25, 28-30], cell necrosis, digestion of pancreas and its 
surroundings [19-21].  
AP is known to involve reactive oxygen (ROS) and reactive nitrogen (RNS) species, that together 
with calcium overload leads to abnormal mitochondrial Ca2+ uptake [25,30] and opening of the 
mitochondrial permeability transition pore (MPTP) [32,33] resulting in reduction of ATP production. 
The lack of ATP together with calcium overload and protease activation leads to acinar cells necrosis 
generating the damaging inflammatory response [5].  
Asparaginase-induced pancreatitis 
Recently another form of AP has been studied in detail, a well-known complication of the treatment 
of childhood acute lymphoblastic leukaemia (ALL). The incidence of AP following childhood ALL 
treatment is between 7- 18% [34]. Whilst numerous anti-leukemic medications have been reported, 
the most important are based on Asparaginase [34]. The development of AP is one of the commonest 
causes for stopping Asparaginase treatment, because re-exposure is associated with recurrence of 
pancreatitis [35]. However, stopping the scheduled Asparaginase treatment because of previous 
pancreatitis has been linked to an increased relapse rate [36]. While significant progress has been 
made in characterizing the effects of alcohol and bile acids on pancreas [5,23,37,38], the 
Asparaginase-induced pancreatic pathology was largely unknown.  
Findings presented recently [39] provide the first mechanistic insight into the process by which 
Asparaginase treatment of ALL may cause Asparaginase-induced AP (AAP). Pancreatic acinar cells 
can respond to a very low dose (0.1IU/ml, Fig. 2A) and in practically all cases to higher doses of 
Asparaginase (Fig.2B). The most accessible therapeutic target in Asparaginase-elicited toxicity is the 
Ca2+ release activated Ca2+ (CRAC) channel in pancreatic acinar cells (PACs) [23,40]. The 
Asparaginase-induced Ca2+ elevations (plateau) depend on CRAC channels and were markedly 
diminished by the inhibitor GSK-7975A [39]. Consequently, Asparaginase-induced necrosis was 
dramatically reduced by GSK-7975A to near control levels (Fig. 3A). The protective effects of CRAC 
channel inhibitors against alcohol-induced pancreatitis in isolated pancreatic acinar cells [23,26] and 
in pancreatic stellate cells [41,42] have been confirmed by in vivo studies [43]. Therefore, this 
approach is also likely to succeed against AAP [39] and the next step would be to test the 
effectiveness of CRAC channel blockade against AAP using an in vivo mouse model.  
The AAP mechanism is apparently fundamentally different from the therapeutic action of 
Asparaginase on lymphoblastic cells in ALL [44]. The Asparaginase effect on cancer cells relies on 
depletion of asparagine, which the malignant cells cannot produce themselves, in contrast to normal 
cells [44], whereas the side-effect of Asparaginase, namely AAP, is owing to activation of a signal 
transduction mechanism involving PAR2 (Fig. 3A,C) but independent of asparagine [39]. Hence, 
several potential intervention points are available for treating the side effect of Asparaginase (Fig.3C). 
The key initiation site of Asparaginase action on PACs seems to be PAR2. This receptor has 
previously been implicated in AP, although its exact role is still debated [45,46]. Blocking PAR2 has 
inhibited both the pathological [Ca2+]i elevations and the Asparaginase-induced necrosis (Fig.3A) 
[39], suggesting that PAR2 inhibitors could be a useful tool to supplement Asparaginase ALL 
treatment in AAP cases. Both Ca2+ entry and extrusion were significantly affected by Asparaginase 
while sustained elevation of [Ca2+]i is responsible for the necrosis [39]. The simplest explanation for 
this is the reduction in the intracellular ATP level, limiting energy supply and, therefore, inhibiting 
plasma membrane Ca2+ ATPase [39]. Restoring energy supply by the addition of pyruvate (Fig.3A) 
provided a high degree of protection against pancreatic necrosis. The established mechanism of action 
of Asparaginase (Fig.3B) has been confirmed for several sources of Asparaginase, including the drug 
ELSPAR and PEG-Asparaginase and including Asparaginase from both E Coli and Erwinia 
chrysanthemi (Fig. 3B). These findings should allow the start of designing new treatments for AAP. 
 
 
How to save PACs from Ca2+ overload and necrosis?   
Interestingly, AAP and AP induced by other more common causes are not so much different [39]. 
Calcium overload, loss of ATP and massive necrosis are also the main features of AP induced by 
alcohol and bile. Therefore, current developments in AP field are undoubtedly applicable to AAP 
[39]. It has been shown previously that pharmacological inhibition of IP3Rs in pancreatic acinar cells 
or knock out of IP3Rs of type 2 and 3 in mice significantly diminished POAEE-elicited intracellular 
trypsin activity rise [37]. These data indicate that these intracellular channels are involved in critical 
steps of cytosolic Ca2+ overload, necrosis and AP progression. Attempts to protect acinar cells against 
Ca2+ overload by inhibition of Ca2+ release from the internal stores are problematic due to the lack of 
specific inhibitors of IP3Rs and RyRs. 
The intracellular Ca2+ sensor calmodulin is known as a regulator of many intracellular targets 
including intracellular Ca2+ receptor channels and this ability can be exploited to reduce Ca2+ overload 
[38]. Calmodulin activator Ca2+like peptides 3 (CALP-3) at a concentration of 100 M was shown to 
be effective in regulation of alcohol-induced Ca2+ release and cell necrosis [38] without affecting the 
physiologically relevant ACh and CCK-induced oscillations [38,47]. A much more potent analogue of 
CALP-3 was recently developed [48], which is effective at much lower concentrations starting from 
0.1 M and therefore, has a good potential for cytosolic Ca2+ regulation.  
Another recently published finding is based on the ability of high concentrations of caffeine to inhibit 
IP3Rs [49]; however, this development is still in its early stages. Alternatively, Bcl-2 family proteins 
have been shown to regulate Ca2+ release via binding to the intracellular Ca2+ channels, inhibiting Ca2+ 
release and regulating Ca2+ homeostasis. These Bcl-2 proteins therefore provide an additional 
therapeutic avenue in controlling intracellular Ca2+ overload in acute pancreatitis. The BH4 domain of 
Bcl-2 was shown to inhibit IP3Rs and RyRs at low concentrations [50,51]. Inhibition of NAADP-
induced signalling, e.g. Ned-19 is also worth considering particularly for bile acid induced AP [52].  
While inhibition of Ca2+ release is rather difficult to utilise and none of the directions mentioned 
above is in the clinical trial stage, inhibition of store operated Ca2+ entry as a potential tool for AP 
therapy is much more developed [26, 43]. CRAC channel blockers GSK7579A (GlaxoSmithKline, 
UK) and CM_128 (CalciMedica, US) have been remarkably successful in in vitro and in vivo models 
of AP, inhibiting all major disease hallmarks (Fig. 3C) [26,43].  Therefore, the developments of 
CRAC channel blockers might lead to a first specific therapy for AP. 
Early observation that cells supplied with ATP can tolerate even high stress from AP-related 
pathologies [28], could eventually become an important part in future AP treatment. A systematic 
review by Mosztbacher et al 2017 [53] concluded that restoration of energy level can help in some 
forms of AP. While pyruvate is very effective for in vitro experiments in protecting acinar cells 
against L-Asparaginase-triggered damage [39], a simple derivative of pyruvic acid, namely, ethyl 
pyruvate has been found useful for treatment of bile-induced AP in a rat model [54].  Ethyl pyruvate 
is also known as a ROS scavenger and, in addition, has other anti-inflammatory effects [55]. The role 
of ROS in AP remains controversial [30, 56,57, 58], while a recent study has shown an important 
contribution of nitric oxide [31] in pancreatic pathology, justifying the use of NO synthase inhibitors 
as a potential AP treatment [59,60]. In spite of a number of developments, some more advanced than 
others and it is possible that combination of drugs will have to be used eventually while their target 
might not be limited to the PACs. 
 
Potential role of pancreatic stellate cells in AP 
PSC research has recently received increasing attention due to our growing understanding of this cell 
type’s involvement in pancreatic health and disease [41,42,61,62]. 
The first discovery of PSCs 35 years ago, [63] was followed by the development of PSC culturing 
techniques in the 90’s [64]. Recent pioneer studies using pancreatic lobules preparation have 
introduced new possibilities for investigating PSCs in their natural environment [41,42,61]. The 
advantage of lobule research is the unique opportunity to study the contribution and communication 
of different pancreatic cell types in response to physiological and pathological stimuli.   
It has been generally accepted that under physiological conditions PCSs show characteristics of the 
normal quiescent state (qPSCs); however, their function in the pancreas is largely unknown. It has 
been suggested that qPSCs regulate the normal architecture of pancreatic tissue by regulating the 
synthesis and degradation of extracellular matrix (ECM) by the production of matrix 
metalloproteinase (MMPs) and tissue inhibitors of MMPs (TIMP) [65]. qPSCs can be recognised as 
small elongated cells located in the peri-acinar space with retinol/vitamin A-containing lipid droplets 
that can be visualized by intrinsic multiphoton fluorescence [41]. They also express a cytoskeletal 
protein desmin (Fig. 4A) and glial fibrillary acid protein (GFAP) [41,61].      
Fluo-4 
During pancreatic injury, or culturing, qPSCs can be transformed to their activated state (aPSCs) that 
is highly implicated in fibrosis and desmoplastic reactions in chronic pancreatitis (CP) and pancreatic 
cancer, respectively [66-69]. 
However, our recently published data have disputed the accepted general concept of the quiescence of 
normal PSCs [41]. On the contrary, this cell type shows an extraordinary sensitivity to very small 
changes in the blood pressure-lowering nonapeptide bradykinin (BK) while PACs are completely 
insensitive to BK (Fig. 4B, C) [41]. 
BK was discovered for the first time in the late 40’s and described as a plasma protein that induced a 
slow delayed muscle contraction in isolated guinea pig ileum (brady means slow; kinein means to 
move, to stimulate in Greek) [70,71]. Along with other kinins, BK belongs to a family of bioactive 
peptides produced from plasma protein kininogens by endogenous proteolytic enzymes kallikreins of 
kallikrein–kinin system (KKS) that controls many physiological and pathological functions. The BK 
normal plasma level was found within the range of 40-70 pM [72,73]. 
It has been show previously that in pancreatic tissue kallikrein is mainly stored as the pro-enzyme pre-
kallikrein in the acinar cell zymogen granules [74]. In acute pancreatitis, kallikrein would leak from 
damaged necrotic cells leading to a rise in BK production from the basal level in plasma to up to ∼140 pM [72,73]. 
We have found that application of BK at concentrations from as low as 100 pM to a maximum effect 
at 1 nM reliably evoked cytosolic Ca2+ signals in PSCs by activating bradykinin type 2 receptors (B2 
receptors) [41]. These data demonstrate that any increase in the BK plasma level above the normal 
range would induce a robust Ca2+ response in PSCs that has a direct link with acute pancreatitis 
development. 
Recently published data have shown that BK-induced Ca2+signals in PSCs do not evoke any change in 
[Ca2+]i in neighbouring PACs (Fig. 4B,C) [41]. There are, of course, possibilities for the involvement 
of alternative pathways. The beneficial effect of pharmacological blockade of the B2 receptor to 
supress acute pancreatitis has been shown previously [73,75-78]. Using the model of isolated 
pancreatic lobules, it was shown that B2 receptor blockade markedly reduced the level of acinar 
necrosis induced by major pancreatitis-inducing agents such as ethanol, FAEEs or bile acids [41]. 
However, the exact pathway(s) that link the functions of PACs and PSCs in pancreatic health and 
disease remains unclear. 
Conclusion 
There are very promising developments in this area. Several approaches are now competing, but in the 
end, a combination of approaches might be needed to successfully treat AP. On the other hand, 
different treatments might be better suited for different causes of AP, rather than one for all. Further 
research in this area is necessary to utilise the findings and move to the development of potential 
drugs. 
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Figure legends 
Figure 1. Model of the NAADP-induced Ca2+ release in pancreatic acinar cells. A very small primary 
Ca2+ release from an acid store (endosomes, lysosomes) being amplified very substantially by further 
Ca2+ release from both larger acid stores (zymogen granules) and the ER (Modified from [16]). 
 
Figure 2. Asparaginase induces calcium responses in PACs in dose-dependent manner. A. 
Representative trace of Asparaginase (0.1IU/ml)-induced calcium spikes in PACs. B. The average 
trace of 200IU/ml Asparaginase-induced cytosolic calcium plateau response. Traces were averaged 
and shown with error bars. Cells were loaded with Fluo-4 AM.  
 
 
Fig. 3. Asparaginase-induced necrosis can be inhibited using three different approaches. A. 
Asparaginase (200 IU/ml) induces a substantial level of necrosis in PACs. The CRAC channel 
inhibitor GSK-7975A (10 µM) essentially abolished Asparaginase-induced necrosis to the control 
level (p>0.24), but significantly (p<0.0001) lower than that caused by 200 IU/ml of Asparaginase 
alone. PAR2 inhibitor (10 M FSLLRY-NH2) significantly blocked the Asparaginase-induced 
necrosis (p<0.0001). Pyruvate (1 mM) also significantly (p<0.0001) reduced the Asparaginase-
induced necrosis to practically control level [34]. B. Asparaginase from different sources induce 
comparable level of necrosis. Abcam (number of tested cells n=1124), Elspar (n= 1708) and 
PEGylated Asparaginase (n=1317), all induce significant necrosis as compared to control (p<0.0001 
for all three sources). C. Schematic diagram illustrating the effects of Asparaginase on PACs. 
Potential sites for therapeutic intervention (PAR2, calcium release, calcium entry, and ATP depletion) 
are also indicated. 
 
 
Figure 4. A. The representative image of staining of pancreatic lobule with desmin antibody, detected 
by conjugated secondary antibody IgG-CruzFluor 594 (CFL594), overlaid with transmitted light 
image and with DAPI stained nuclei. B. Fluorescent image of freshly isolated mouse pancreatic 
cluster loaded with Fluo-4 in AM form. PSCs are shown as small elongated cells highlighted with red 
arrow; blue arrow is pointing to location of a neighbouring PAC. C. A representative cytosolic Ca2+ 
traces from PSC and PAC indicated in B: red trace from the PSC and blue trace from the PAC. 
Application of 1 nM BK results in a typical biphasic Ca2+ elevation in the PSC but not in the 
neighbouring PAC. Subsequent additions of 10 μM ACh and 10 μM CCh induce Ca2+ signals only in 
the PAC with no effect on PSCs. (Modified from [36]). 
 
 
